Procter & Gamble's Valuation Story: Undervalued or Overpriced?

Procter & Gamble's recent product launches have sparked renewed attention on the company's innovation pipeline and its stock valuation. The Febreze x Dunkin' scent collection and Olay's updated Repair Serum Body Wash line are among the new offerings that have generated buzz. However, despite this excitement, Procter & Gamble's share price has remained relatively stable.

The stock is currently trading at $146.92, with a 7-day return of 2.64% and a year-to-date return of 3.62%. In contrast, the 1-year total shareholder return has declined by 4.99%. This mixed sentiment suggests that investors remain cautious as they weigh new product activity against margin pressures and questions around organic growth.

Despite being priced above its most popular narrative fair value of $107.52, Procter & Gamble's valuation multiple assumes steady but unspectacular compounding. The company is expected to grow its revenues at a rate of 3%, converging with the economy's growth rate of 4.69%. However, this narrative also acknowledges potential risks, including competitive pressure on margins and any slowdown in revenue growth.

A different view comes from the SWS DCF model, which estimates Procter & Gamble's fair value at $196.96 per share, representing a 25.4% premium to its current price. This valuation suggests that the stock is undervalued, contrary to the most popular narrative.